DelveInsight’s, “Adult-Onset Still Disease Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Adult-Onset Still Disease pipeline landscape. It covers the Adult-Onset Still Disease pipeline drug profiles, including Adult-Onset Still Disease clinical trials and nonclinical stage products. It also covers the Adult-Onset Still Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Recent Developmental Activities in the Adult-Onset Still Disease Treatment Landscape
Request a sample and discover the recent breakthroughs happening in the Adult-Onset Still Disease Pipeline landscape @ Adult-Onset Still Disease Pipeline Outlook
Adult-Onset Still Disease Overview
Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that affects the entire body (systemic disease). The cause of the disorder is unknown (idiopathic). It has similar symptoms to systemic-onset juvenile idiopathic arthritis – fever, rash, and joint pain. The specific symptoms and frequency of episodes vary from one person to another and the progression of the disorder is difficult to predict. In some individuals, the disorder appears suddenly, disappears almost as quickly and may not return. In other people, adult-onset Still’s disease is a chronic, potentially disabling, condition.
Key Takeaways from the Adult-Onset Still Disease Pipeline Report
For further information, refer to the detailed Adult-Onset Still Disease Drugs Launch, Adult-Onset Still Disease Developmental Activities, and Adult-Onset Still Disease News, click here for Adult-Onset Still Disease Ongoing Clinical Trial Analysis
Adult-Onset Still Disease Emerging Drugs Profile
Tadekinig alfa: AB2 Bio Ltd.
Tadekinig alfa is the drug name for recombinant human interleukin-18 binding protein (IL-18BP). It is currently under phase 2 of clinical trials for the indication Adult-onset Still’s disease.
CERC-007: Cerecor
CERC-007 is a fully human anti-IL-18 monoclonal antibody with the potential to address multiple auto-inflammatory diseases, including Adult-onset Still’s disease (AOSD) and multiple myeloma (MM). IL-18 is a pro-inflammatory cytokine; patients with AOSD and MM shows elevated levels of IL-18. Cerecor seeks to initiate a phase 1b/2a proof-of-concept study of CERC-007 in AOSD and MM patients in 2020.
Tocilizumab (TCZ) – Roche
TCZ is a humanized anti-IL-6R antibody that binds to both soluble and membranebound IL-6 receptors (sIL-6R and mIL-6R), inhibiting sIL-6R and mIL-6R-mediated signaling. TCZ is available for intravenous (IV) infusion and subcutaneous (SC) injections. It is registered for the indication Adult-onset Still’s disease.
Anakinra – Swedish Orphan Biovitrum
Anakinra is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). The drug is produced by recombinant DNA technology using an E. coli bacterial expression system. Anakinra is useful for treating rheumatoid arthritis (RA) and some other inflammatory conditions. It is registered for the indication Adult-onset Still’s disease.
Adult-Onset Still Disease Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Adult-Onset Still Disease. The companies which have their Adult-Onset Still Disease drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AB2 Bio Ltd. and others.
Find out more about the Adult-Onset Still Disease Pipeline Segmentation, Therapeutics Assessment, and Adult-Onset Still Disease Emerging Drugs @ Adult-Onset Still Disease Treatment Landscape
Scope of the Adult-Onset Still Disease Pipeline Report
Dive deep into rich insights for drugs for Adult-Onset Still Disease Pipeline Companies and Therapies, click here @ Adult-Onset Still Disease Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Adult-Onset Still Disease Mergers and acquisitions, Adult-Onset Still Disease Licensing Activities @ Adult-Onset Still Disease Recent Trends, and Future Perspectives
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services